Original article
COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update

https://doi.org/10.1016/j.msard.2021.102929Get rights and content
Under a Creative Commons license
open access

Highlights

  • We report on 272 cladribine tablets (CladT)-treated patients who acquired COVID-19.

  • Of the total evaluable cohort, 40 (15%) experienced serious COVID-19.

  • Median onset of COVID-19 from recent preceding CladT treatment course was 162 days.

  • 51% of patients were recovered/recovering at time of analysis (to 15 January 2021).

Abstract

Background

We previously summarized outcomes for 46 cladribine tablets (CladT)-treated patients with multiple sclerosis (MS) and confirmed or suspected COVID-19, as reported to the Merck KGaA Global Patient Safety Database. This report updates on these findings, to 15 January 2021, for a total of 272 reported cases of COVID-19 among CladT recipients.

Methods

Case definitions: confirmed (COVID-19 diagnostic test was positive); suspected (no confirmatory test performed/reported). Cases fulfilling the criteria of hospitalized, medically significant, or fatal were designated as serious and outcomes were classified per usual pharmacovigilance practice.

Results

The evaluable cohort comprised 261 patients (confirmed COVID-19, n=160; suspected, n=101); an additional 11 patients had symptoms compatible with COVID-19 but were not evaluated further given their negative diagnostic tests. Median time to onset of COVID-19 from the most recent preceding CladT treatment course was 162 days (n=139). Outcomes were: recovered/recovering, n=133 (51%); not recovered/not resolved, n=19 (7%); died, n=1 (0.4%); and not reported/missing/pending, n=108 (41%). Of the total cohort, 40 (15%) experienced serious COVID-19.

Conclusion

Our results suggest that CladT-treated patients with MS are generally not at greater risk of serious disease and/or a severe outcome with COVID-19 compared with the general population and other patients with MS who acquired COVID-19.

Key words

Cladribine tablets
COVID-19
Multiple sclerosis

Cited by (0)